You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EDSS

Showing 26 - 50 of 988
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Novel Functional Eye-Tracking Software Application for Multiple

Recruiting
  • Multiple Sclerosis
  • Eye-Tracking
  • Montreal, Quebec, Canada
  • +1 more
Dec 14, 2022

Multiple Sclerosis Trial in Worldwide (SAR443820, Placebo)

Recruiting
  • Multiple Sclerosis
  • Bruxelles, Belgium
  • +16 more
Jan 31, 2023

Validation of the BeCare Multiple Sclerosis Assessment App

Enrolling by invitation
  • Multiple Sclerosis
    • New Haven, Connecticut
      Yale University School of Medicine
    Dec 22, 2022

    Neuromyelitis Optica Spectrum Disorder Relapse Trial in Tianjin (Ruxolitinib)

    Withdrawn
    • Neuromyelitis Optica Spectrum Disorder Relapse
    • Tianjin, Tianjin, China
      Tianjin Medical University General Hospital
    Jun 10, 2023

    Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • serum Neurofilament Filament Light chain (sNfL) monitoring
    • Basel, Basel Stadt, Switzerland
    • +7 more
    Oct 17, 2023

    NMO Spectrum Disorder Trial in Tianjin (Baricitinib)

    Not yet recruiting
    • NMO Spectrum Disorder
    • Tianjin, Tianjin, China
      Tianjin Medical University General Hospital
    Mar 18, 2023

    Silent Progression Activity Monitoring - SPAM Study

    Not yet recruiting
    • Multiple Sclerosis
    • NO INTERVENTION
    • Nice, France
      CHU de Nice
    Dec 5, 2022

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    Completed
    • Multiple Sclerosis
    • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    • Prague, Czechia
      IMPULS Endowment Fund
    Mar 7, 2023

    Multiple Sclerosis, Progressive Multiple Sclerosis Trial in Bergen (Nicotinamid riboside, Placebo)

    Not yet recruiting
    • Multiple Sclerosis
    • Progressive Multiple Sclerosis
    • Nicotinamid riboside
    • Placebo
    • Bergen, Norway
      Haukeland University Hospital
    Feb 22, 2023

    Multiple Sclerosis Trial in Amman (Telko plus conventional physical therapy (CPT))

    Recruiting
    • Multiple Sclerosis
    • Telko plus conventional physical therapy (CPT)
    • Amman, Jordan
      Isra University
    Aug 2, 2022

    Multiple Sclerosis, Relapsing-Remitting Trial in Munich, Mainz, Münster (Vivomixx®, Conjugated linoleic acid (CLA/Tonalin® FFA

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Vivomixx®
    • +3 more
    • Munich, Bavaria, Germany
    • +2 more
    Jun 15, 2023

    Multiple Sclerosis Trial in Montreal (Eye-Tracking)

    Not yet recruiting
    • Multiple Sclerosis
    • Eye-Tracking
    • Montreal, Quebec, Canada
      Genge Partners, Inc.
    Dec 13, 2022

    Multiple Sclerosis Trial in Elazig (Yoga)

    Not yet recruiting
    • Multiple Sclerosis
    • Yoga
    • Elazığ, Turkey
      Gülcan Bahçecioğlu TURAN
    Nov 7, 2023

    Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

    Not yet recruiting
    • Relapsing-remitting Multiple Sclerosis
    • CT-P53
    • +2 more
    • (no location specified)
    Jun 7, 2023

    Multiple Sclerosis Trial in New York (Intrathecal MSC-NP injection, Intrathecal saline injection)

    Active, not recruiting
    • Multiple Sclerosis
    • Intrathecal MSC-NP injection
    • Intrathecal saline injection
    • New York, New York
      Tisch MS Research Center of New York
    Oct 25, 2022

    MS - a Prospective Cohort Study

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • +2 more
    • PASS-MS
    • Berlin, Germany
      Experimental and Clinical Research Center, Studienambulanz Neuro
    Aug 9, 2021

    OFSEP Very High Definition Cohort

    Not yet recruiting
    • Multiple Sclerosis
    • MRI
    • Lyon, France
    • +4 more
    Nov 14, 2022

    Insulin Resistance in Egyptian Patients With Multiple Sclerosis

    Not yet recruiting
    • Multiple Sclerosis
    • Insulin Resistance
    • treatment of insulin resistance with appropriate modality according to each patient
    • (no location specified)
    Aug 28, 2023

    Multiple Sclerosis, Magnetic Resonance Spectroscopy Trial (magnetic resonance spectroscopy)

    Not yet recruiting
    • Multiple Sclerosis
    • Magnetic Resonance Spectroscopy
    • magnetic resonance spectroscopy
    • (no location specified)
    Aug 3, 2022

    Secondary Progressive Multiple Sclerosis (SPMS) Trial in Tel Aviv (SCM-010)

    Not yet recruiting
    • Secondary Progressive Multiple Sclerosis (SPMS)
    • SCM-010
    • Tel Aviv, Israel
      Tel Aviv Medical Center
    Oct 26, 2022

    Ataxia, Multiple Sclerosis Trial

    Not yet recruiting
    • Ataxia
    • Multiple Sclerosis
      • (no location specified)
      Oct 14, 2022

      Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis Trial in Tijuana (Tolerogenic Fibroblasts)

      Completed
      • Multiple Sclerosis, Relapsing-Remitting
      • Multiple Sclerosis
      • Tolerogenic Fibroblasts
      • Tijuana, Baja California, Mexico
        Servicios Medicos UCC, S.C.
      Oct 14, 2021

      Multiple Sclerosis, Internuclear Ophthalmoplegia Trial in Amsterdam (Clemastine Fumarate, Placebo)

      Recruiting
      • Multiple Sclerosis
      • Internuclear Ophthalmoplegia
      • Clemastine Fumarate
      • Placebo
      • Amsterdam, Netherlands
        Amsterdam UMC, location VUmc
      Sep 21, 2022

      NMO Spectrum Disorder, Azathioprine Adverse Reaction Trial in Nanning (Azathioprine)

      Completed
      • NMO Spectrum Disorder
      • Azathioprine Adverse Reaction
      • Nanning, Guangxi, China
        Qingmeng Huang
      Jun 8, 2023

      Quality of Life of Multiple Sclerosis Patients Treated With

      Not yet recruiting
      • Multiple Sclerosis (MS)
      • ofatumumab
      • (no location specified)
      Nov 27, 2023